Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways
CC139 fibroblasts are one of several model systems in which the Raf --> MEK --> ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of...
Gespeichert in:
Veröffentlicht in: | Oncogene 2003-03, Vol.22 (9), p.1281-1293 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1293 |
---|---|
container_issue | 9 |
container_start_page | 1281 |
container_title | Oncogene |
container_volume | 22 |
creator | Weston, Claire R Balmanno, Kathryn Chalmers, Claire Hadfield, Kathryn Molton, Sarah A Ley, Rebecca Wagner, Erwin F Cook, Simon J |
description | CC139 fibroblasts are one of several model systems in which the Raf --> MEK --> ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of Bim(EL), a proapoptotic 'BH3-only' member of the Bcl-2 protein family. Bim(EL) expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK --> c-Jun pathway was neither necessary nor sufficient to induce Bim(EL) expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of Bim(EL). Furthermore, selective activation of the ERK1/2 pathway by deltaRaf-1:ER* substantially reduced Bim(EL) expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of deltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --> PDK --> PKB pathway. Thus, serum withdrawal-induced expression of Bim(EL) occurs independently of the JNK --> c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73082655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73082655</sourcerecordid><originalsourceid>FETCH-LOGICAL-p543-d4c5b7cee534f44484c98336ed486302aa05970551ed8e69a3500087dfb707213</originalsourceid><addsrcrecordid>eNo1UEtPwzAYywHExuAvoJy4VaR5NCm3MZUxOgGqdq_S5qta1BdNCvTf08G42LJkW7LP0JKEgnghZXSBLq19J4TIkNALtPBp4Csp2BKV69xVn9pVXYu7AkdJ7N9RnE3YQO10ogvPv48SPEA_gLVg8UPVYPj-VcdM1RroYYbW1dOxwZWAn19i3A34bcdi3GtXfunJXqHzQtcWrk-8QofH6LB58vav291mvfd6wZlneC4ymQMIxgvOueJ5qBgLwHAVMEK1JiKURAgfjIIg1EzMq5Q0RSaJpD5bodu_2n7oPkawLm0qm0Nd6xa60aaSEUUDIWbjzck4Zg2YtB-qRg9T-n8N-wHnz1yl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73082655</pqid></control><display><type>article</type><title>Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways</title><source>MEDLINE</source><source>SpringerLink Journals (MCLS)</source><source>EZB Free E-Journals</source><source>Springer Nature - Connect here FIRST to enable access</source><creator>Weston, Claire R ; Balmanno, Kathryn ; Chalmers, Claire ; Hadfield, Kathryn ; Molton, Sarah A ; Ley, Rebecca ; Wagner, Erwin F ; Cook, Simon J</creator><creatorcontrib>Weston, Claire R ; Balmanno, Kathryn ; Chalmers, Claire ; Hadfield, Kathryn ; Molton, Sarah A ; Ley, Rebecca ; Wagner, Erwin F ; Cook, Simon J</creatorcontrib><description>CC139 fibroblasts are one of several model systems in which the Raf --> MEK --> ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of Bim(EL), a proapoptotic 'BH3-only' member of the Bcl-2 protein family. Bim(EL) expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK --> c-Jun pathway was neither necessary nor sufficient to induce Bim(EL) expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of Bim(EL). Furthermore, selective activation of the ERK1/2 pathway by deltaRaf-1:ER* substantially reduced Bim(EL) expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of deltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --> PDK --> PKB pathway. Thus, serum withdrawal-induced expression of Bim(EL) occurs independently of the JNK --> c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations.</description><identifier>ISSN: 0950-9232</identifier><identifier>PMID: 12618753</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Apoptosis - drug effects ; Apoptosis Regulatory Proteins ; bcl-2-Associated X Protein ; Bcl-2-Like Protein 11 ; Butadienes - pharmacology ; Carrier Proteins - biosynthesis ; Carrier Proteins - genetics ; Cell Line - drug effects ; Cell Line - metabolism ; Chromones - pharmacology ; Cricetinae ; Cricetulus ; Culture Media, Serum-Free - pharmacology ; Cycloheximide - pharmacology ; Cysteine Endopeptidases - pharmacology ; Cysteine Proteinase Inhibitors - pharmacology ; Dactinomycin - pharmacology ; Enzyme Activation - drug effects ; Enzyme Inhibitors - pharmacology ; Fibroblasts - metabolism ; JNK Mitogen-Activated Protein Kinases ; Lung ; Membrane Proteins ; Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors ; Mitogen-Activated Protein Kinase 1 - metabolism ; Mitogen-Activated Protein Kinase 3 ; Mitogen-Activated Protein Kinases - antagonists & inhibitors ; Mitogen-Activated Protein Kinases - metabolism ; Mitogen-Activated Protein Kinases - physiology ; Morpholines - pharmacology ; Nitriles - pharmacology ; Nucleic Acid Synthesis Inhibitors - pharmacology ; Phosphatidylinositol 3-Kinases - physiology ; Phosphoinositide-3 Kinase Inhibitors ; Protein Serine-Threonine Kinases - genetics ; Protein Serine-Threonine Kinases - metabolism ; Protein Structure, Tertiary ; Protein Synthesis Inhibitors - pharmacology ; Proto-Oncogene Proteins - metabolism ; Proto-Oncogene Proteins c-bcl-2 ; Proto-Oncogene Proteins c-raf - genetics ; Proto-Oncogene Proteins c-raf - physiology ; Recombinant Fusion Proteins - metabolism ; RNA, Messenger - biosynthesis ; RNA, Messenger - genetics ; Signal Transduction - drug effects ; Signal Transduction - physiology</subject><ispartof>Oncogene, 2003-03, Vol.22 (9), p.1281-1293</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12618753$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weston, Claire R</creatorcontrib><creatorcontrib>Balmanno, Kathryn</creatorcontrib><creatorcontrib>Chalmers, Claire</creatorcontrib><creatorcontrib>Hadfield, Kathryn</creatorcontrib><creatorcontrib>Molton, Sarah A</creatorcontrib><creatorcontrib>Ley, Rebecca</creatorcontrib><creatorcontrib>Wagner, Erwin F</creatorcontrib><creatorcontrib>Cook, Simon J</creatorcontrib><title>Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways</title><title>Oncogene</title><addtitle>Oncogene</addtitle><description>CC139 fibroblasts are one of several model systems in which the Raf --> MEK --> ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of Bim(EL), a proapoptotic 'BH3-only' member of the Bcl-2 protein family. Bim(EL) expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK --> c-Jun pathway was neither necessary nor sufficient to induce Bim(EL) expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of Bim(EL). Furthermore, selective activation of the ERK1/2 pathway by deltaRaf-1:ER* substantially reduced Bim(EL) expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of deltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --> PDK --> PKB pathway. Thus, serum withdrawal-induced expression of Bim(EL) occurs independently of the JNK --> c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations.</description><subject>Animals</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis Regulatory Proteins</subject><subject>bcl-2-Associated X Protein</subject><subject>Bcl-2-Like Protein 11</subject><subject>Butadienes - pharmacology</subject><subject>Carrier Proteins - biosynthesis</subject><subject>Carrier Proteins - genetics</subject><subject>Cell Line - drug effects</subject><subject>Cell Line - metabolism</subject><subject>Chromones - pharmacology</subject><subject>Cricetinae</subject><subject>Cricetulus</subject><subject>Culture Media, Serum-Free - pharmacology</subject><subject>Cycloheximide - pharmacology</subject><subject>Cysteine Endopeptidases - pharmacology</subject><subject>Cysteine Proteinase Inhibitors - pharmacology</subject><subject>Dactinomycin - pharmacology</subject><subject>Enzyme Activation - drug effects</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fibroblasts - metabolism</subject><subject>JNK Mitogen-Activated Protein Kinases</subject><subject>Lung</subject><subject>Membrane Proteins</subject><subject>Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors</subject><subject>Mitogen-Activated Protein Kinase 1 - metabolism</subject><subject>Mitogen-Activated Protein Kinase 3</subject><subject>Mitogen-Activated Protein Kinases - antagonists & inhibitors</subject><subject>Mitogen-Activated Protein Kinases - metabolism</subject><subject>Mitogen-Activated Protein Kinases - physiology</subject><subject>Morpholines - pharmacology</subject><subject>Nitriles - pharmacology</subject><subject>Nucleic Acid Synthesis Inhibitors - pharmacology</subject><subject>Phosphatidylinositol 3-Kinases - physiology</subject><subject>Phosphoinositide-3 Kinase Inhibitors</subject><subject>Protein Serine-Threonine Kinases - genetics</subject><subject>Protein Serine-Threonine Kinases - metabolism</subject><subject>Protein Structure, Tertiary</subject><subject>Protein Synthesis Inhibitors - pharmacology</subject><subject>Proto-Oncogene Proteins - metabolism</subject><subject>Proto-Oncogene Proteins c-bcl-2</subject><subject>Proto-Oncogene Proteins c-raf - genetics</subject><subject>Proto-Oncogene Proteins c-raf - physiology</subject><subject>Recombinant Fusion Proteins - metabolism</subject><subject>RNA, Messenger - biosynthesis</subject><subject>RNA, Messenger - genetics</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - physiology</subject><issn>0950-9232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1UEtPwzAYywHExuAvoJy4VaR5NCm3MZUxOgGqdq_S5qta1BdNCvTf08G42LJkW7LP0JKEgnghZXSBLq19J4TIkNALtPBp4Csp2BKV69xVn9pVXYu7AkdJ7N9RnE3YQO10ogvPv48SPEA_gLVg8UPVYPj-VcdM1RroYYbW1dOxwZWAn19i3A34bcdi3GtXfunJXqHzQtcWrk-8QofH6LB58vav291mvfd6wZlneC4ymQMIxgvOueJ5qBgLwHAVMEK1JiKURAgfjIIg1EzMq5Q0RSaJpD5bodu_2n7oPkawLm0qm0Nd6xa60aaSEUUDIWbjzck4Zg2YtB-qRg9T-n8N-wHnz1yl</recordid><startdate>20030306</startdate><enddate>20030306</enddate><creator>Weston, Claire R</creator><creator>Balmanno, Kathryn</creator><creator>Chalmers, Claire</creator><creator>Hadfield, Kathryn</creator><creator>Molton, Sarah A</creator><creator>Ley, Rebecca</creator><creator>Wagner, Erwin F</creator><creator>Cook, Simon J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20030306</creationdate><title>Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways</title><author>Weston, Claire R ; Balmanno, Kathryn ; Chalmers, Claire ; Hadfield, Kathryn ; Molton, Sarah A ; Ley, Rebecca ; Wagner, Erwin F ; Cook, Simon J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p543-d4c5b7cee534f44484c98336ed486302aa05970551ed8e69a3500087dfb707213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis Regulatory Proteins</topic><topic>bcl-2-Associated X Protein</topic><topic>Bcl-2-Like Protein 11</topic><topic>Butadienes - pharmacology</topic><topic>Carrier Proteins - biosynthesis</topic><topic>Carrier Proteins - genetics</topic><topic>Cell Line - drug effects</topic><topic>Cell Line - metabolism</topic><topic>Chromones - pharmacology</topic><topic>Cricetinae</topic><topic>Cricetulus</topic><topic>Culture Media, Serum-Free - pharmacology</topic><topic>Cycloheximide - pharmacology</topic><topic>Cysteine Endopeptidases - pharmacology</topic><topic>Cysteine Proteinase Inhibitors - pharmacology</topic><topic>Dactinomycin - pharmacology</topic><topic>Enzyme Activation - drug effects</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fibroblasts - metabolism</topic><topic>JNK Mitogen-Activated Protein Kinases</topic><topic>Lung</topic><topic>Membrane Proteins</topic><topic>Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors</topic><topic>Mitogen-Activated Protein Kinase 1 - metabolism</topic><topic>Mitogen-Activated Protein Kinase 3</topic><topic>Mitogen-Activated Protein Kinases - antagonists & inhibitors</topic><topic>Mitogen-Activated Protein Kinases - metabolism</topic><topic>Mitogen-Activated Protein Kinases - physiology</topic><topic>Morpholines - pharmacology</topic><topic>Nitriles - pharmacology</topic><topic>Nucleic Acid Synthesis Inhibitors - pharmacology</topic><topic>Phosphatidylinositol 3-Kinases - physiology</topic><topic>Phosphoinositide-3 Kinase Inhibitors</topic><topic>Protein Serine-Threonine Kinases - genetics</topic><topic>Protein Serine-Threonine Kinases - metabolism</topic><topic>Protein Structure, Tertiary</topic><topic>Protein Synthesis Inhibitors - pharmacology</topic><topic>Proto-Oncogene Proteins - metabolism</topic><topic>Proto-Oncogene Proteins c-bcl-2</topic><topic>Proto-Oncogene Proteins c-raf - genetics</topic><topic>Proto-Oncogene Proteins c-raf - physiology</topic><topic>Recombinant Fusion Proteins - metabolism</topic><topic>RNA, Messenger - biosynthesis</topic><topic>RNA, Messenger - genetics</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weston, Claire R</creatorcontrib><creatorcontrib>Balmanno, Kathryn</creatorcontrib><creatorcontrib>Chalmers, Claire</creatorcontrib><creatorcontrib>Hadfield, Kathryn</creatorcontrib><creatorcontrib>Molton, Sarah A</creatorcontrib><creatorcontrib>Ley, Rebecca</creatorcontrib><creatorcontrib>Wagner, Erwin F</creatorcontrib><creatorcontrib>Cook, Simon J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Oncogene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weston, Claire R</au><au>Balmanno, Kathryn</au><au>Chalmers, Claire</au><au>Hadfield, Kathryn</au><au>Molton, Sarah A</au><au>Ley, Rebecca</au><au>Wagner, Erwin F</au><au>Cook, Simon J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways</atitle><jtitle>Oncogene</jtitle><addtitle>Oncogene</addtitle><date>2003-03-06</date><risdate>2003</risdate><volume>22</volume><issue>9</issue><spage>1281</spage><epage>1293</epage><pages>1281-1293</pages><issn>0950-9232</issn><abstract>CC139 fibroblasts are one of several model systems in which the Raf --> MEK --> ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of Bim(EL), a proapoptotic 'BH3-only' member of the Bcl-2 protein family. Bim(EL) expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK --> c-Jun pathway was neither necessary nor sufficient to induce Bim(EL) expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of Bim(EL). Furthermore, selective activation of the ERK1/2 pathway by deltaRaf-1:ER* substantially reduced Bim(EL) expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of deltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --> PDK --> PKB pathway. Thus, serum withdrawal-induced expression of Bim(EL) occurs independently of the JNK --> c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations.</abstract><cop>England</cop><pmid>12618753</pmid><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0950-9232 |
ispartof | Oncogene, 2003-03, Vol.22 (9), p.1281-1293 |
issn | 0950-9232 |
language | eng |
recordid | cdi_proquest_miscellaneous_73082655 |
source | MEDLINE; SpringerLink Journals (MCLS); EZB Free E-Journals; Springer Nature - Connect here FIRST to enable access |
subjects | Animals Apoptosis - drug effects Apoptosis Regulatory Proteins bcl-2-Associated X Protein Bcl-2-Like Protein 11 Butadienes - pharmacology Carrier Proteins - biosynthesis Carrier Proteins - genetics Cell Line - drug effects Cell Line - metabolism Chromones - pharmacology Cricetinae Cricetulus Culture Media, Serum-Free - pharmacology Cycloheximide - pharmacology Cysteine Endopeptidases - pharmacology Cysteine Proteinase Inhibitors - pharmacology Dactinomycin - pharmacology Enzyme Activation - drug effects Enzyme Inhibitors - pharmacology Fibroblasts - metabolism JNK Mitogen-Activated Protein Kinases Lung Membrane Proteins Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors Mitogen-Activated Protein Kinase 1 - metabolism Mitogen-Activated Protein Kinase 3 Mitogen-Activated Protein Kinases - antagonists & inhibitors Mitogen-Activated Protein Kinases - metabolism Mitogen-Activated Protein Kinases - physiology Morpholines - pharmacology Nitriles - pharmacology Nucleic Acid Synthesis Inhibitors - pharmacology Phosphatidylinositol 3-Kinases - physiology Phosphoinositide-3 Kinase Inhibitors Protein Serine-Threonine Kinases - genetics Protein Serine-Threonine Kinases - metabolism Protein Structure, Tertiary Protein Synthesis Inhibitors - pharmacology Proto-Oncogene Proteins - metabolism Proto-Oncogene Proteins c-bcl-2 Proto-Oncogene Proteins c-raf - genetics Proto-Oncogene Proteins c-raf - physiology Recombinant Fusion Proteins - metabolism RNA, Messenger - biosynthesis RNA, Messenger - genetics Signal Transduction - drug effects Signal Transduction - physiology |
title | Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T16%3A33%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation%20of%20ERK1/2%20by%20deltaRaf-1:ER%20represses%20Bim%20expression%20independently%20of%20the%20JNK%20or%20PI3K%20pathways&rft.jtitle=Oncogene&rft.au=Weston,%20Claire%20R&rft.date=2003-03-06&rft.volume=22&rft.issue=9&rft.spage=1281&rft.epage=1293&rft.pages=1281-1293&rft.issn=0950-9232&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E73082655%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73082655&rft_id=info:pmid/12618753&rfr_iscdi=true |